Clinical Efficacy Observation of Kanglaite Injection Combined with PD-1/PD-L1 Inhibitors and Chemotherapy in Treatment of Non-Small Cell Lung Cancer
Objective To observe the clinical efficacy and safety of Kanglaite Injection(KLTI)combined with PD-1/PD-L1 inhibitors and chemotherapy in the first-line treatment of non-small cell lung cancer(NSCLC),providing a basis for the clinical treatment of NSCLC.Methods A total of 64 NSCLC patients admitted to the First Affiliated Hospital of the University of Science and Technology of China from January 2020 to December 2023 were included.They were divided into observation group(30 cases)and control group(34 cases)based on whether KLTI was used.The objective response rate(ORR),disease control rate(DCR),KPS score,tumor markers(CEA,CYFRA21-1),and adverse reactions were compared between the two groups.Results Compared with the control group,there was no statistically significant difference in ORR,DCR and KPS scores in the observation group(P＞0.05).The decrease in tumor markers CEA and CYFRA21-1 before and after treatment was significant(P＜0.05);There was no statistically significant difference in adverse reactions between the two groups(P＞0.05).Conclusion KLTI assisted PD-1/PD-L1 inhibitor combined with chemotherapy for fiirst-line treatment of NSCLC can reduce serum CEA and CYFRA21-1 levels,improve physical condition to a certain extent,enhance quality of life,and is safe and reliable.
Kanglaite InjectionPD-1/PD-L1 inhibitorschemotherapynon-small cell lung cancer
万方数据
维普
